腹膜纤维化机制与治疗新进展

刘玲玲; 成蔚; 周伟东; 潘金英; 黄波

doi:10.3969/j.issn.1674-4500.2016.04.28

腹膜纤维化机制与治疗新进展

doi: 10.3969/j.issn.1674-4500.2016.04.28

1.
南方医科大学珠江医院肾内科，广东广州 510280
2.
福建省立医院血液透析科，福建福州 350001

详细信息

作者简介:
刘玲玲，在读研究生，E-mail: 1176452365@qq.com

计量
- 文章访问数: 529
- HTML全文浏览量: 214
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2016-04-04
- 刊出日期: 2016-04-01

Mechanisms and prospects of interventions in the peritoneal fibrosis

1.
Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China
2.
Department of Hemodialysis, Fujian Provincial Hospital, Fujian 350001, China

摘要

摘要: 腹膜透析作为一种有效的肾脏替代治疗，在终末期肾病中运用日渐广泛，甚至成为肾脏替代治疗的首选方案。但长期的腹膜透析会导致腹膜功能下降、腹膜结构改变，最终演变成腹膜纤维化，甚至包裹性腹膜硬化症，使超滤失败，严重时使患者退出腹膜透析。目前国内外研究主要包括：上皮细胞一间充质转化、腹膜透析液的生物不相容性、血管紧张素一醛固酮系统、氧化应激、腹膜炎症、全身微炎症状态、基因调控、生长及转化因子等，针对上述发病机制，提出了相应的治疗方法。
- 腹膜纤维化 /
- 机制 /
- 治疗
Abstract: As an effective renal replacement therapy, peritoneal dialysis is widely used in patients with end-stage kidney disease.However, long-term peritoneal dialysis will progress to peritoneal fibrosis even encapsulating peritoneal sclerosis with functional and structural alterations of the peritoneal membrane. Peritoneal fibrosis can cause the failure of ultrafiltration and eventually make patients withdrawal from PD. The objective of this review is to summarize the mechanisms of peritoneal fibrosis from a new perspective, and conclude current and future prospects of interventions in the peritoneal fibrosis.
- peritoneal fibrosis /
- mechanisms /
- interventions

HTML全文

参考文献(51)

[1]	Taranu T, Florea L, Paduraru D, et al. Morphological changes of the peritoneal membrane in patients with long-term dialysis[J]. Romanian Journal of Morphology and Embryology, 2014, 55(3): 927-32. http://www.ncbi.nlm.nih.gov/pubmed/25329122
[2]	Kinashi H, Ito Y, Mizuno M, et al. TGF-beta 1 Promotes Lymphangiogenesis during Peritoneal Fibrosis[J]. Journal of the American Society of Nephrology, 2013, 24(10): 1627-42. doi: 10.1681/ASN.2012030226
[3]	Kawanishi K, Honda K, Tsukada M, et al. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis[J]. Perit Dial Int, 2013, 33(3): 242-51. doi: 10.3747/pdi.2011.00270
[4]	Ullian ME, Luttrell LM, Lee MH, et al. Stimulation of cyclooxygenase 2 expression in rat peritoneal mesothelial cells[J]. Nephron Exp Nephrol, 2014, 25(8): 14. https://www.ncbi.nlm.nih.gov/pubmed/25531215
[5]	Onishi A, Akimoto T, Urabe M, et al. Attenuation of methylglyoxalinduced peritoneal fibrosis: immunomodulation by interleukin-10 [J]. Laboratory Investigation, 2015, 95(12): 1353-62. doi: 10.1038/labinvest.2015.110
[6]	Yucel SK, Arikan H, Tugtepe H, et al. Cysteinyl1 receptor antagonist montelukast, does not prevent peritoneal membrane damage in experimental chronic peritoneal dialysis model in rats[J]. Kidney Blood Press Res, 2014, 39(6): 648-57. doi: 10.1159/000368477
[7]	Liu KY, Yorozuya T, Adachi N, et al. Suppression of peritoneal thickening by histamine in a mouse model of peritoneal scraping [J]. Clin Exp Nephrol, 2015, 19(4): 562-6. doi: 10.1007/s10157-014-1027-5
[8]	Rodrigues-Diez R, Aroeira LS, Orejudo MA, et al. IL-17A is a novel player in dialysis-induced peritoneal damage[J]. Kidney Int, 2014, 86(2): 303-15. doi: 10.1038/ki.2014.33
[9]	Liu JY, Zeng LL, Zhao YL, et al. Selenium suppresses Lipopolysaccharide-Induced fibrosis in peritoneal mesothelial cells through inhibition of Epithelial-to-Mesenchymal transition[J]. Biol Trace Elem Res, 2014, 161(2): 202-9. doi: 10.1007/s12011-014-0091-8
[10]	Wakabayashi K, Hamada C, Kanda R, et al. Oral astaxanthin supplementation prevents peritoneal fibrosis in rats[J]. Peritoneal Dialysis International, 2015, 35(5): 506-16. doi: 10.3747/pdi.2013.00317
[11]	Thiery JP, Acloque H, Huang RY, et al. Epithelial-Mesenchymal transitions in development and disease[J]. Cell, 2009, 139(5): 871-90. doi: 10.1016/j.cell.2009.11.007
[12]	Loureiro J, Aguilera A, Selgas R, et al. Blocking TGF-beta1 protects the peritoneal membrane from dialysate-induced damage[J]. J Am Soc Nephrol, 2011, 22(9): 1682-95. doi: 10.1681/ASN.2010111197
[13]	Yang Y, Liu K, Liang Y, et al. Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-beta1/Smad3 signaling pathway in vitro[J]. Int J Clin Exp Pathol, 2015, 8(3): 2746-54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440089/
[14]	Yang CY, Chau YP, Lee HT, et al. Cannabinoid receptors as therapeutic targets for Dialysis-Induced peritoneal fibrosis[J]. Am J Nephrol, 2013, 37(1): 50-8. doi: 10.1159/000345726
[15]	Lu Y, Gao L, Li L, et al. Hydrogen sulfide alleviates peritoneal fibrosis via attenuating inflammation and TGF-beta1 synthesis[J]. Nephron, 2015, 131(3): 210-9. doi: 10.1159/000441504
[16]	Chaudhary K, Moore H, Tandon A, et al. Nanotechnology and adeno-associated virus-based decorin gene therapy ameliorates peritoneal fibrosis[J]. Am J Physiol Renal Physiol, 2014, 307(7): F777-82. doi: 10.1152/ajprenal.00653.2013
[17]	Kushiyama T, Oda T, Yamada M, et al. Effects of liposomeencapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats[J]. Nephrology Dialysis Transplantation, 2011, 26(10): 3143-54. doi: 10.1093/ndt/gfr068
[18]	Kato H, Mizuno T, Mizuno M, et al. Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model[J]. Nephrology Dialysis Transplantation, 2012, 27(2): 526-36. doi: 10.1093/ndt/gfr302
[19]	Shin HS, Ryu ES, Oh ES, et al. Endoplasmic reticulum stress as a novel target to ameliorate epithelial-to-mesenchymal transition and apoptosis of human peritoneal mesothelial cells[J]. Laboratory Investigation, 2015, 95(10): 1157-73. doi: 10.1038/labinvest.2015.91
[20]	Yung S, Chan T M. Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells[J]. Mediators Inflamm, 2012, 20(12): 484167. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337720/
[21]	Kitamura S, Horimoto N, Tsuji K, et al. The selection of peritoneal mesothelial cells is important for cell therapy to prevent peritoneal fibrosis[J]. Tissue Eng Part A, 2014, 20(3/4): 529-39. https://www.ncbi.nlm.nih.gov/pubmed/24007428
[22]	Chen KS, Wang CH, Yen TH, et al. Potential role of bone marrowderived cells in the turnover of mesothelium[J]. Ren Fail, 2010, 32 (9): 1081-7. doi: 10.3109/0886022X.2010.509901
[23]	Sekiguchi Y, Hamada C, Ro Y, et al. Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model[J]. Journal of Artificial Organs, 2012, 15(3): 272-82. doi: 10.1007/s10047-012-0648-2
[24]	Shen J, Zheng J, Saxena R, et al. Novel source of human hematopoietic stem cells from peritoneal dialysis effluents[J]. Stem Cell Res, 2015, 15(2): 299-304. doi: 10.1016/j.scr.2015.07.003
[25]	Wang N, Li QG, Zhang L, et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6[J]. PLoS One, 2012, 7(8): e43768. doi: 10.1371/journal.pone.0043768
[26]	Wakabayashi K, Hamada C, Kanda R, et al. Adipose-derived mesenchymal stem cells transplantation facilitate experimental peritoneal fibrosis repair by suppressing epithelial-mesenchymal transition[J]. J Nephrol, 2014, 27(5): 507-14. doi: 10.1007/s40620-014-0133-5
[27]	Ang L, Zhuang S. The role of tyrosine kinase receptors in peritoneal fibrosis[J]. Perit Dial Int, 2015, 35(5): 497-505. doi: 10.3747/pdi.2014.00171
[28]	Peng W, Zhou Q, Ao X, et al. Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis[J]. Ren Fail, 2013, 35(7): 958-66. doi: 10.3109/0886022X.2013.808565
[29]	Iiu J, Bao J, Hao J, et al. HSP70 inhibits high glucose-induced Smad3 activation and attenuates epithelial-to-mesenchymal transition of peritoneal mesothelial cells[J]. Mol Med Rep, 2014, 10 (2): 1089-95. http://www.ncbi.nlm.nih.gov/pubmed/24890460
[30]	Ata Y, Nishino T, Kushibiki T, et al. HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice[J]. Acta Biomater, 2012, 8(7): 2688-96. doi: 10.1016/j.actbio.2012.03.050
[31]	Margetts PJ, Hoff C, Liu L, et al. Transforming growth factor beta-induced peritoneal fibrosis is mouse strain dependent[J]. Nephrol Dial Transplant, 2013, 28(8): 2015-27. doi: 10.1093/ndt/gfs289
[32]	Ang K, Zhang H, Zhou X, et al. miRNA589 regulates epithelialmesenchymal transition in human peritoneal mesothelial cells[J]. J Biomed Biotechnol, 2012, 20, (12): 673096. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479401/
[33]	Li XJ, Sun L, Xiao L, et al. Gene delivery in peritoneal dialysis related peritoneal fibrosis research[J]. Chin Med J (Engl), 2012, 125 (12): 2219-24. https://www.ncbi.nlm.nih.gov/pubmed/22884156
[34]	Lin F, Wu X, Zhang H, et al. A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis [J]. BMC Nephrol, 2015, 16(7): 48. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546227/
[35]	Oshizawa H, Morishita Y, Watanabe M, et al. TGF-beta(1)-siRNA delivery with nanoparticles inhibits peritoneal fibrosis[J]. Gene Ther, 2015, 22(4): 333-40. doi: 10.1038/gt.2014.116
[36]	Amamoto D, Takai S, Hirahara I, et al. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy[J]. Clin Chim Acta, 2010, 411(9/10): 762-4. http://www.ncbi.nlm.nih.gov/pubmed/20184869
[37]	Chuinski AF, Baroni G, Pecoits FR, et al. Evaluation of the use of captopril on peritoneal fibrosis induced in rats by the use of glucose solution 4.25%[J]. J Bras Nefrol, 2013, 35(4): 273-8. doi: 10.5935/0101-2800.20130046
[38]	Hang L, Hao JB, Ren LS, et al. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis[J]. Lab Invest, 2014, 94(8): 839-50. doi: 10.1038/labinvest.2014.69
[39]	Zhang L, Liu J, Liu Y, et al. Fluvastatin inhibits the expression of fibronectin in human peritoneal mesothelial cells induced by high-glucose peritoneal dialysis solution via SGK1 pathway[J]. Clin Exp Nephrol, 2015, 19(3): 336-42. doi: 10.1007/s10157-014-0991-0
[40]	Baroni G, Schuinski AF, Berticelli PT, et al. The influence of simvastatin in induced peritoneal fibrosis in rats by peritoneal dialysis solution with glucosis 4.25%[J]. Acta Cir Bras, 2012, 27 (4): 350-6. doi: 10.1590/S0102-86502012000400012
[41]	Ng YH, Shin HS, Sun CH, et al. Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells[J]. Lab Invest, 2013, 93(2): 194-206. doi: 10.1038/labinvest.2012.166
[42]	Rtunc F, Lang F. Mineralocorticoid and SGK1-sensitive inflammation and tissue fibrosis[J]. Nephron Physiol, 2014, 128(1/ 2): 35-9. https://www.ncbi.nlm.nih.gov/pubmed/25377230
[43]	Lee YC, Hung SY, Liou HH, et al. Vitamin D can ameliorate chlorhexidine gluconate-induced peritoneal fibrosis and functional deteriorationthrough the inhibition of epithelial-to-mesenchymal transition of mesothelial cells[J]. Biomed Res Int, 2015, 1: 595030. http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26495304/
[44]	Eker K, Inal A, Sayar I, et al. Prevention of intraabdominal adhesions by local and systemic administration of immunosuppressive drugs[J]. Iran Red Crescent Med J, 2013, 15(12): e14148. http://www.ncbi.nlm.nih.gov/pubmed/24693396
[45]	Uddam B, Basaran M, Kocak G, et al. The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis[J]. Int Urol Nephrol, 2015, 47(8): 1423-8. doi: 10.1007/s11255-015-1015-z
[46]	Iong C, Liu N, Fang L, et al. Suramin inhibits the development and progression of peritoneal fibrosis[J]. J Pharmacol Exp Ther, 2014, 351(2): 373-82. doi: 10.1124/jpet.114.215228
[47]	I J, Guo ZY, Gao XH, et al. Low molecular weight heparin(LMWH) improves peritoneal function and inhibits peritoneal fibrosis possibly through suppression of HIF-1alpha, VEGF and TGF-beta1 [J]. PLoS One, 2015, 10(2): e118481. http://www.ncbi.nlm.nih.gov/pubmed/25723475
[48]	Rata K, Maruyama S, Kato S, et al. Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice[J]. Am J Physiol Renal Physiol, 2009, 297(6): F1510-7. doi: 10.1152/ajprenal.90330.2008
[49]	U W. Zhang Y, sigdel K R.the effects of panax notoginseng saponins on the cytokines and peritoneal function in rats with peritoneal fibrosis[J]. Ren Fail, 2015, 37(9): 1507-13. doi: 10.3109/0886022X.2015.1088350
[50]	Tamura M, Nishino T, Obata Y, et al. The kampo medicine Daikenchuto inhibits peritoneal fibrosis in mice[J]. Biol Pharm Bull, 2015, 38(2): 193-200. doi: 10.1248/bpb.b14-00469
[51]	Ou SM, Hu FH, Yang WC, et al. Far-infrared Therapy as a Novel Treatment for Encapsulating Peritoneal Sclerosis[J]. American Journal of Gastroenterology, 2014, 109(12): 1957-9. doi: 10.1038/ajg.2014.352

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 529
HTML全文浏览量: 214
PDF下载量: 2
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

腹膜纤维化机制与治疗新进展

doi: 10.3969/j.issn.1674-4500.2016.04.28

作者简介:
刘玲玲，在读研究生，E-mail: 1176452365@qq.com

计量

Mechanisms and prospects of interventions in the peritoneal fibrosis

计量

目录

留言板

腹膜纤维化机制与治疗新进展

doi: 10.3969/j.issn.1674-4500.2016.04.28

作者简介: 刘玲玲，在读研究生，E-mail: 1176452365@qq.com

计量

出版历程

Mechanisms and prospects of interventions in the peritoneal fibrosis

计量

出版历程

目录

作者简介:
刘玲玲，在读研究生，E-mail: 1176452365@qq.com